Patent ID: 8735381
Filing Date: 2014-05-27
Classification: A61K,A61P

Abstract:
1. A method for treating an estrogen dependent condition selected from the group consisting of endometriosis and uterine fibroids comprising intermittent administration of a composition comprising an effective amount of a selective progesterone receptor modulator (SPRM) selected from CDB-4124 (21-methoxy-17α-acetoxy-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione) and 17α-acetoxy-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-dien-3,20-dione to a female in need thereof, said intermittent administration comprising administering said composition daily or every other day for a period of at least 30 days beginning during the luteal phase of said female's menstrual cycle, then discontinuing said administration by means of a continual lack of treatment for a period of days sufficient to allow the female to menstruate then administering the composition daily or every other day for a period of at least 30 days, then discontinuing said administration by means of a continual lack of treatment for a period of days sufficient to allow the female to menstruate, and repeating this pattern of administration and discontinuance of administration for as long as necessary to achieve treatment of said conditions.